DOP058: Does biologic therapy increase the risk for fistula-associated mucinous adenocarcinoma in long standing perianal Crohn’s Disease?ECCO'17 Barcelona 2017
1
DOP060: Real-world treatment pathway visualizations show low use of biologic therapies in Crohn’s Disease and Ulcerative Colitis in the United StatesECCO'17 Barcelona 2017
1
DOP062: Biosimilar infliximab (CT-P13) is not inferior to originator infliximab: Explorative IBD subgroup-analyses in Crohn’s Disease and ulcerative colitis from the NOR-SWITCH trialECCO'17 Barcelona 2017
1
DOP063: Serial tuberculin skin test improves the detection of latent tuberculosis infection in Inflammatory Bowel Disease patientsECCO'17 Barcelona 2017
1
DOP064: High rate of advanced neoplasia after detection of low-grade dysplasia in Inflammatory Bowel Disease patients with primary sclerosing cholangitisECCO'17 Barcelona 2017
1
DOP065: Use of chromoendoscopy versus white light endoscopy for colorectal cancer surveillance in Inflammatory Bowel Disease patients with primary sclerosing cholangitis; a six year experienceECCO'17 Barcelona 2017
1
DOP066: Strict surveillance colonoscopy should be performed for the Ulcerative Colitis patients who underwent ileorectal anastomosisECCO'17 Barcelona 2017
1
DOP067: Risk of malignant and non-malignant complications of the rectal stump in patients with Inflammatory Bowel DiseaseECCO'17 Barcelona 2017
1
DOP069: Natural history of dysplasia and colorectal cancer in IBD patients in Belgium tertiary care centersECCO'17 Barcelona 2017
1
DOP070: Endoscopic response to induction therapy with TNF inhibitors is the best predictor of long term mucosal healing in Crohn’s DiseaseECCO'17 Barcelona 2017
1
DOP073: Submucosal injection of the oligonucleotide STNM01 is able to induce clinical remission, mucosal healing and histological response in left-sided Ulcerative Colitis patients with moderate-to-severe diseaseECCO'17 Barcelona 2017
1
DOP074: Pharmacokinetics and exposure-response of tofacitinib in a Phase 3 maintenance study in Ulcerative Colitis patientsECCO'17 Barcelona 2017
1
DOP075: Efficacy of filgotinib, a selective JAK1 inhibitor, is independent of prior anti-TNF exposure: Subgroup analysis of the phase 2 FITZROY study in moderate-to-severe Crohn' DiseaseECCO'17 Barcelona 2017
1
DOP076: A Phase 2B, multicenter, randomised, placebo-controlled dose-ranging trial of peficitinab, an OralL JAK Inhibitor, in patients with moderately to severely active Ulcerative ColitisECCO'17 Barcelona 2017
1
DOP079: The role of intestinal transplant in patients with complicated Inflammatory Bowel Disease (IBD): The Cambridge experienceECCO'17 Barcelona 2017
1